GlassScriptPhysician profile
Suzana E Morgan
NPI 1235378027
$3,277.27
in general payments reported to CMS, 2019-2025
28 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $96.10 · 2021: $19.69 · 2022: $14.05 · 2023: $534 · 2024: $862 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.04 |
| Education | $168.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $798.90 | 2019-2025 | Benlysta |
| Amgen INC. | $593.68 | 2019-2025 | Tavneos, Uplizna, Enbrel |
| Abbvie INC. | $362.75 | 2019-2025 | |
| Janssen Biotech, INC. | $290.11 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $270.66 | 2019-2025 | |
| Genentech USA, INC. | $198.37 | 2019-2025 | Actemra |
| Pfizer INC. | $105.69 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $105.28 | 2024-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $74.64 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $61.58 | 2019-2020 | |
| Organon LLC | $48.20 | 2024-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.38 | 2019-2025 | Cyltezo, Ofev |
| Sobi, INC | $40.05 | 2019-2025 | |
| Radius Health, INC. | $39.57 | 2019-2025 | Tymlos |
| Sandoz INC. | $35.97 | 2024-2025 | Hyrimoz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $28.02 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.74 | 2024 | Saphnelo |
| Fresenius Kabi USA, LLC | $16.60 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $15.98 | 2024 | Acthar |
| Celltrion USA INC. | $14.95 | 2023 | Yuflyma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.05 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.90 | 2024 | Zoryve |
| Celgene Corporation | $13.88 | 2019 | |
| Medexus Pharma, INC. | $13.70 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2019 | |
| Antares Pharma, INC. | $12.71 | 2019 | |
| Horizon Therapeutics Plc | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzana Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.